Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Carcinoma, Renal Cell 22Carcinoma, Hepatocellular 7Kidney Neoplasms 6Osteosarcoma 5Sarcoma, Ewing 4Neoplasm Metastasis 4Sarcoma 3Clear-cell metastatic renal cell carcinoma 3Recurrence 2Prostatic Neoplasms 2Neuroendocrine Tumors 2Neoplasms 2Colorectal Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Non-Small-Cell Lung 2Carcinoma 2Adrenocortical Carcinoma 2von Hippel-Lindau Disease 1Wilms Tumor 1Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Urachal adenocarcinoma 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sjogren's Syndrome 1Scleroderma, Systemic 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Refractory Differentiated Thyroid Gland Carcinoma 1

Interventions

lutetium Lu 177 dotatate 1cabozantinib 1Sunitinib 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Metastatic Digestive System Neuroendocrine Tumor G1 × cabozantinib × Clear all
NCT05773274 2026-06-03

Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial

National Cancer Institute (NCI)

Phase 2 Recruiting
100 enrolled
EndocrineNET

Metastatic Digestive System Neuroendocrine Tumor G1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡